ICF004
/ Changfeng Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 25, 2026
CF PharmTech, Inc…announced that the Investigational New Drug (“IND”) application for ICF004, the Company’s internally developed first-in-class (FIC) inhaled dry powder candidate for the treatment of pulmonary fibrosis (a Class 1 chemical drug candidate), has been accepted by the National Medical Products Administration of China (“NMPA”).
(Financial Times)
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1